Some people with multiple sclerosis notice a worsening of symptoms between doses of disease modifying therapies such as ocrevus, rituximab, and briumvi. This video explains the symptoms and shows concern for the practice of aggressively dosing these medications frequently to minimize symptoms.
No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS): https://pubmed.ncbi.nlm.nih.gov/37674...
Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing – similar clinical efficacy with decreased immunoglobulin M deficiency rates: https://www.clinicalkey.com/#!/conten...
Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited): Indication: Management of adult patients with early primary progressive multiple sclerosis as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity: https://www.ncbi.nlm.nih.gov/books/NB...
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis: https://link.springer.com/article/10....
Comment or ask questions below! I would be happy to answer!
Subscribe on YouTube for more videos every Wednesday!
Make video requests in the comments section!
Check out my book “Resilience in the Face of Multiple Sclerosis” FREE on Amazon: https://amazon.com/dp/B07WP7H5LK It's about 5 people with MS who live incredible lives, the science and psychology of resilience, mindfulness, and ho’oponopono. Paperback priced to generate $0 royalty.
Dr. Brandon Beaber is a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system. He is a partner in the Southern California Permanente Medical Group and practices in Downey, California (South Los Angeles). He has several publications on MS epidemiology and has participated in clinical trials for MS therapeutics. You can follow him on twitter @Brandon_Beaber where he regularly posts about MS news and research.
Follow me on twitter: Twitter: Brandon_Beaber
Music: INNER GRACE - Copyright 2018 Wilton Vought Source: Really Really Free Music Link: Video T
he video material by Dr. Brandon Beaber is general educational material on health conditions and is not intended to be used by viewers to diagnose or treat any individual's medical condition. Specifically, this material is not a substitute for individualized diagnostic and treatment advice by a qualified medical/health practitioner, licensed in your jurisdiction, who has access to the relevant information available from diagnostic testing, medical interviews, and a physical examination. To the extent that Dr. Beaber endorses any lifestyle change, behavioral intervention, or supplements, the viewer should consult with a qualified healthcare professional to determine the safety and efficacy of the intervention in light of their individualized information.
Some people with multiple sclerosis notice a worsening of symptoms between doses of disease modifying therapies such as ocrevus, rituximab, and briumvi. This video explains the symptoms and shows concern for the practice of aggressively dosing these medications frequently to minimize symptoms.
No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS): https://pubmed.ncbi.nlm.nih.gov/37674...
Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing – similar clinical efficacy with decreased immunoglobulin M deficiency rates: https://www.clinicalkey.com/#!/conten...
Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited): Indication: Management of adult patients with early primary progressive multiple sclerosis as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity: https://www.ncbi.nlm.nih.gov/books/NB...
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis: https://link.springer.com/article/10....
Comment or ask questions below! I would be happy to answer!
Subscribe on YouTube for more videos every Wednesday!
Make video requests in the comments section!
Check out my book “Resilience in the Face of Multiple Sclerosis” FREE on Amazon: https://amazon.com/dp/B07WP7H5LK It's about 5 people with MS who live incredible lives, the science and psychology of resilience, mindfulness, and ho’oponopono. Paperback priced to generate $0 royalty.
Dr. Brandon Beaber is a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system. He is a partner in the Southern California Permanente Medical Group and practices in Downey, California (South Los Angeles). He has several publications on MS epidemiology and has participated in clinical trials for MS therapeutics. You can follow him on twitter @Brandon_Beaber where he regularly posts about MS news and research.
Follow me on twitter: Twitter: Brandon_Beaber
Music: INNER GRACE - Copyright 2018 Wilton Vought Source: Really Really Free Music Link: Video T
he video material by Dr. Brandon Beaber is general educational material on health conditions and is not intended to be used by viewers to diagnose or treat any individual's medical condition. Specifically, this material is not a substitute for individualized diagnostic and treatment advice by a qualified medical/health practitioner, licensed in your jurisdiction, who has access to the relevant information available from diagnostic testing, medical interviews, and a physical examination. To the extent that Dr. Beaber endorses any lifestyle change, behavioral intervention, or supplements, the viewer should consult with a qualified healthcare professional to determine the safety and efficacy of the intervention in light of their individualized information.
I had the crap gap every time my next infusion was approaching, the first two times, I had never heard of the crap gap. Eventually, he agreed, in conjunction with the folks at Genentech, moved me to a five month infusion regimen. It reduced the crap gap to about two weeks, which was acceptable to me. In 2023, I was forced to relocate back to Texas, and had to of course, change doctors. The VA in San Antonio does have an MS clinic, and I was placed with one of the neurologists. Great guy, as sharp as my previous doctor, much more personable. After all the tests again minus the CSF test, he put me back on a six month infusion regimen. This started in 2024. It's a process to get onboarded with the VA after you move. Anyways, here I am, a month out from my next infusion, and though I am feeling a bit more fatigue than in recent days, it's because I have been a LOT more active, just in the last few days.
After speaking with my neurologist, as well as nutritionists, dieticians, and weight management specialists in the VA, everybody is in agreement that much of my improvement in how I feel, can be tied to the dietary changes I have made over the last three years. I have moved to a much heavier intake of proteins and natural fats, as well as whole foods, in comparison to eating a lot of heavily processed foods. I have also been intermittently fasting for the last two years, not deliberately, but just how my eating pattern evolved. I cut out almost all processed sugar and HFCS, and on those times I DO consume some, I can feel the inflammation within an hour. As of my last meeting with my doctor, he feels confident that I am no longer progressing due to no new lesions in my last two years of MRIs, and my EDSS hasn't progressed (still 5.5).
I would suggest to anyone with MS, regardless the medication you are taking, to seriously evaluate your diet, and at least consider adopting a whole foods and low/no processed sugar diet.